Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
30.4M
-
Shares change
-
+4.07M
-
Total reported value, excl. options
-
$197M
-
Value change
-
+$26.7M
-
Put/Call ratio
-
0.06
-
Number of buys
-
42
-
Number of sells
-
-24
-
Price
-
$6.47
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q4 2020
88 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q4 2020.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.4M shares
of 108M outstanding shares and own 28.09% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (3.27M shares), Rock Springs Capital Management LP (2.68M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.25M shares), VR Adviser, LLC (1.95M shares), Sofinnova Investments, Inc. (1.91M shares), Parkman Healthcare Partners LLC (1.88M shares), Vivo Capital, LLC (1.65M shares), Foresite Capital Management III, LLC (1.62M shares), EcoR1 Capital, LLC (1.51M shares), and Samsara BioCapital, LLC (1.36M shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.